

WHAT IS CLAIMED ARE:

Af

1. In a therapeutic composition comprising a BPI protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improved composition comprising a bactericidal-activity-enhancing poloxamer surfactant.
2. The therapeutic composition of claim 1 further comprising EDTA.
3. The improved composition of claim 1 wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.
4. The therapeutic composition of claim 3 further comprising EDTA.
5. In a method for treating a bacterial infection comprising administering a composition of BPI protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improvement comprising administering a therapeutic composition of BPI protein product and bactericidal-activity-enhancing poloxamer surfactant.
6. The improved method of claim 5 wherein the therapeutic composition further comprises EDTA.
7. The improved method of claim 5 wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

09696709-102400

8. The improved method of claim 5 further comprising administering an antibiotic.
9. A composition for inhibiting bacterial and fungal growth comprising a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant.
10. The composition of claim 9 further comprising EDTA.
11. The composition of claim 9 wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.
12. A method for inhibiting bacterial and fungal growth comprising treating the bacteria or fungus with a composition of a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant.
13. The method of claim 12 wherein the composition further comprises EDTA.
14. The method of claim 12 wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

09696709 102400

A1